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Firstly, can you 
talk a little about 
pulmonary arterial 
hypertension 
(PAH)?
PAH is a chronic 
and progressive disease that is characterised 
by the development of increased blood 
pressure (hypertension) in the arteries of 
the lungs. Owing to the fact that pulmonary 
arteries are responsible for carrying blood 
from the right side of the heart to the lungs, 
right heart failure is the most common and 
prominent complication of this disease. 
Eventually, and because of its progressive 
nature, PAH will undermine the efficiency 
of the heart muscle if left untreated and 
ultimately lead to death. 
Despite the fact that PAH was first 
reported in the end of the 19th century, 
its respective diagnosis can be very 
difficult, even in cases where PAH has 
significantly progressed. This is because 
the respective symptoms can be easily 
mistaken for other diseases that propel 
hypertension. The most commonly 
described symptoms reported by patients 
diagnosed with PAH are shortness of 
breath and fatigue. The time between 
patient recognition of symptoms and a 
definitive diagnosis of PAH is consistently 
delayed. Therefore, what is important 
right now is to investigate the 
pathophysiology of this disease and
 focus on preventing progressive 
pulmonary arterial remodelling and on 
treating right ventricular heart failure.
Why are potassium channels important for the 
development of new therapeutic strategies?
First of all, potassium channels are ion 
channels present in cell membranes that 
are selectively permeable to potassium ions. 
There are many different types of potassium 
channels that exist in pulmonary artery 
smooth muscle, each one with different 
and distinct functions that contribute to 
the manifestation of various physiological 
actions and pathological conditions. 
Recently, it was found that the KCNK3 
(TASK1) gene, which encodes a type of 
two-pore domain potassium channel, is 
a predisposing gene for PAH by genetic 
mutation. In addition, we have identified that 
calcium-activated potassium channels seen 
in smooth muscle cells have the capacity to 
change from BKca (Kca1.1) to IKca (Kca3.1) 
predominance in PAH, and hence facilitate 
smooth muscle cell migration, enhance 
proliferation and inhibit apoptosis. 
Therefore, our research focuses on the 
regulation of potassium channels in the 
pulmonary smooth muscle cells and on the 
effects of this regulation on the remodelling, 
proliferation and migration of pulmonary 
artery smooth muscle cells. We need to keep 
in mind that some agents or medications 
can control potassium channel regulation. 
Hence, we are currently investigating the 
effect of several agents on pulmonary 
arterial tone and remodelling. Elucidation 
of the effect of potassium channels on 
pulmonary vasoconstriction and remodelling 
is bound to bring new therapeutic 
strategies into the forefront of our minds.
What are the most important findings of 
your research so far?
One of the primary targets of our research 
is to use Optical Coherence Tomography 
(OCT) in order to investigate and depict 
pulmonary vascular pathologies, and hence 
evaluate pulmonary arterial compliance 
in PAH patients. Our OCT studies have 
already demonstrated that vascular diseases 
are frequently accompanied by prominent 
development of the vasa vasorum - a network 
of small blood vessels that supply the walls 
of large blood vessels. This development 
contributes to vascular remodelling because 
it acts as a mediator, a conduit if you will, that 
allows the delivery of both leukocytes and 
progenitor cells. Moreover, the development 
of vasa vasorum can also have a profound 
effect on the development of systemic-to-
pulmonary arterial blood flow. Furthermore, 
our investigation demonstrated the 
significant correlations between pulmonary 
arterial intima-media layer thickness and 
pulmonary hemodynamics, including 
pulmonary arterial pressure and resistance.
Hence, our OCT findings can be very 
useful when it comes to observing the 
change of pulmonary arterial pathological 
condition along with the treatment. We 
have also implemented an innovative 
echocardiographic technique that when used 
in combination with cardiac catheterisation 
assessment can allow the efficient and 
accelerated early detection and evaluation 
of right heart failure induced by PAH.  l
Impact Objectives
• Study the pathophysiological condition of pulmonary arterial hypertension (PAH) 
• Develop therapeutic methods for the prevention of progressive pulmonary arterial 
remodelling and treatment of right ventricular heart failure
The secrets of pulmonary 
arterial hypertension
Professor Yasunobu Hayabuchi from the Department of Paediatrics, Tokushima University in Japan 
uncovers the role of potassium channels and vasa vasorum in pulmonary hypertension, and discusses 
innovative therapeutic applications to prevent progressive pulmonary arterial remodelling
16   www.impact.pub
Novel therapeutic approaches in 
pulmonary vascular pathologies
Researchers at the Tokushima University, Japan, are creating a step change in the development of 
innovative techniques that depict pulmonary vascular pathological findings and provide an effective tool for 
improving diagnosis and treatment in patients suffering from pulmonary arterial hypertension (PAH)
A significant proportion of patients with 
congenital heart disease, in particular those 
with increased pulmonary blood flow, will 
develop pulmonary arterial hypertension 
(PAH). Research underway by a team at 
the Tokushima University’s Department 
of Paediatrics aims to investigate and 
eventually implement innovative methods 
to diagnose and treat patient suffering 
from this condition. The team is led by 
Professor Yasunobu Hayabuchi, a paediatric 
cardiologist who has published more than 
100 articles in cardiology and cardiovascular 
pathophysiology and is primarily involved in 
treating infants and children suffering from 
congenital heart diseases, who is working 
closely with his colleague Dr Yukako Homma.
PREVENTION IS KEY
‘PAH is a chronic refractory disease with the 
clinical conditions of persistently elevated 
pulmonary arterial pressure and pulmonary 
vascular resistance from various causes, 
and a poor prognosis with progressive 
exacerbation of right heart failure and 
respiratory failure,’ explains Hayabuchi. What 
makes this disease very difficult to diagnose 
in the first place, but even in cases where 
the disease has significantly progressed, is 
that hypertension in the pulmonary artery 
manifests with no apparent reason. Despite 
the fact that the respective symptoms of 
this disease are evident, such as shortness 
of breath, especially during walking or 
exercise, chest pain and fainting episodes, it 
is often hard to identify PAH because these 
symptoms may be confused with other 
diseases that cause hypoxia in blood and 
promote hypertension. 
Nevertheless, say Hayabuchi, the major 
pathological finding that characterises PAH 
is the narrowing of the pulmonary arterial 
lumen that can come as a result of three 
distinct factors. ‘These include abnormal 
constriction of peripheral small pulmonary 
arteries to less than 500μm in diameter, 
vascular remodelling from the over-
proliferation of vascular endothelial, smooth 
muscle, and other cells and resistance to 
apoptosis, and the formation of thrombus 
in the respective affected sites.’
However, and owing to the fact that 
pulmonary arteries carry blood from the right 
side of the heart to the lungs, PAH leads to 
right heart failure and ultimately death if left 
untreated. This is exactly why Hayabuchi 
and his team have dedicated their research 
on investigating the pathophysiology of this 
disease in order to implement innovative 
approaches that can improve the diagnosis 
and the treatment of this disease. ‘We 
study the pathophysiological condition 
of pulmonary arterial hypertension and 
therapeutic methods from the viewpoint of 
the prevention of progressive pulmonary 
arterial remodelling and treatment of right 
ventricular heart failure,’ outlines Hayabuchi.
ROLE OF POTASSIUM CHANNELS
First of all, there are many different types of 
potassium channels with various functions 
that exist in pulmonary artery smooth muscle 
cells, contributing to many physiological actions 
and pathological conditions. ‘The potassium 
channels that exist in vascular smooth muscle 
cells are broadly divided into four classes: 
voltage-gated K+ channels (Kv), Ca2+ -activated 
K+ channels (Kca), two-pore domain K+ 
channels (K2P), and inwardly rectifying K+ 
channels (KIR),’ highlights Hayabuchi. The 
connection between these channels and 
the manifestation of PAH in patients is a 
prominent field of study that has propelled 
various innovative findings. ‘For instance, we 
identified that KCNK3 (TASK1), which encodes 
a type of two-pore domain potassium channel, 
is a predisposing gene for PAH by genetic 
mutation,’ he says. ‘Furthermore, PAH is 
also characterised by a distinctly decreased 
expression of voltage-gated potassium 
channels, particularly KCNA5 (Kv1.5).’  
Therefore, researchers have shifted their focus 
on investigating and evaluating the level of 
involvement of these channels in the onset 
and exacerbation of PAH with the goal of 
regulating and controlling these channels. 
In fact, the latter can be succeeded by means 
of agents or medication that can improve 
the underlying pulmonary arterial tone and 
remodelling. ‘The calcium-activated potassium 
channels seen in smooth muscle cells also 
change from BKca (Kca1.1) to IKca (Kca3.1) 
predominance in PAH due to transformation 
and have effects including the facilitation of 
smooth muscle cell migration, enhancement 
of proliferation, and inhibition of apoptosis,’ 
outlines Hayabuchi. Hence, the elucidation 
of the roles of potassium channels in 
pulmonary vasoconstriction and remodelling 
is promising for the establishment of new 
therapeutic strategies for PAH.
OPTICAL COHERENCE 
TOMOGRAPHY STUDIES
Optical coherence tomography (OCT) is 
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Tissue Doppler Imaging for the evaluation of cardiac 
function in a PAH patient
OCT imaging showing pulmonary artery morphology and 
pathological findings. Development of vasa vasorum is shown  
a non-invasive intravascular imaging modality 
that uses light waves to take cross-section 
pictures with high resolution of up to 
10–20μm. In fact, this imaging modality 
has proven to be a very efficient method 
in terms of identifying and underlying the 
pathophysiology of coronary arteriosclerosis 
in adults, and hence providing an effective 
tool for improving diagnosis and treatment. 
Recently, Hayabuchi and his team have 
published an innovative research study in 
which OCT was also found to be a promising 
tool for the evaluation of the pulmonary 
artery (PA) wall in children suffering from 
congenital heart disease. Furthermore, it 
was also identified that vascular diseases 
are frequently accompanied by prominent 
development of the vasa vasorum - a network 
of small blood vessels that supply the walls 
of large blood vessels - which contributes 
to vascular remodelling. ‘Our OCT studies 
elucidate that pulmonary arterial vaso 
vasorum increased under the condition with 
hypoxia in complex congenital heart disease,’ 
he explains. ‘Development of vaso vasorum 
contributes to vascular remodelling by acting 
as a conduit for the delivery of leukocytes 
and progenitor cells.’ Therefore, OCT is an 
ideal way to observe the change of pulmonary 
arterial pathological condition along with the 
treatment but also to foresee the prognosis 
of the disease.
FUTURE PLANS
The most critical challenge in the quest 
of unlocking the secrets of this disease, 
and hence introducing novel diagnostic 
and therapeutic approaches is that PAH is 
classified into several groups where each 
one may require a unique approach and 
strategy. For instance, idiopathic PAH is 
caused by a specific gene mutation that can 
cause pulmonary hypertension to develop in 
families, also called heritable PAH, whereas 
congenital heart disease patients have 
progressive PAH. ‘PAH and low pulmonary 
arterial compliance induce right heart failure,’ 
observes Hayabuchi. ‘On the other hand, 
in complex congenital heart disease, vasa 
vasorum of pulmonary artery develops and 
results in the pulmonary arterial remodelling.’ 
This underlines that future research needs 
to consider the treatment and prevention 
of these diseases on an individual level. 
Hayabuchi and his team are progressing well 
towards identifying definitive novel methods 
to treat and prevent these conditions, and the 
extensive research already completed by this 
team provides the scaffold upon which future 
studies can be built upon.  l
Our OCT studies elucidate that pulmonary arterial 
vaso vasorum increased under the condition 
with hypoxia in complex congenital heart disease
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